Support and Resistance Basics

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

CLVS


Top 10 Correlated ETFs

CLVS


Top 10 Correlated Stocks

CLVS


In the News

02:18 13 Aug 2022 CLVS

Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss

Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

01:37 13 Aug 2022 CLVS

Why Clovis Oncology Stock Is Sinking Today

The biotech's Q2 financial results are concerning investors today.

01:11 13 Aug 2022 CLVS

Why Is Clovis Oncology (CLVS) Stock Down 10% Today?

Clovis Oncology (NASDAQ: CLVS ) stock is down more than 10% today after posting its second-quarter financial results. The biopharmaceutical company missed on revenue and profits, leading the way for today's selloff.

12:42 13 Aug 2022 CLVS

Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q2 2022 Results - Earnings Call Transcript

Clovis Oncology, Inc. (NASDAQ:CLVS ) Q2 2022 Earnings Conference Call August 8, 2022 8:30 AM ET Company Participants Anna Sussman - VP, IR Patrick Mahaffy - Co-Founder, CEO, President & Executive Director Lindsey Rolfe - EVP, Clinical Development & Pharmacovigilance and Chief Medical Officer Daniel Muehl - EVP & CFO Conference Call Participants Operator Good morning. My name is Samantha, and I will be your conference operator today.

08:30 13 Aug 2022 CLVS

7 Penny Stocks to Buy Before the Bull Market Returns

In recent weeks, the stock market has stabilized after June's sell-off, but it may take time before bullishness makes a comeback. Plenty of uncertainty remains, including further interest rate hikes, continued high inflation, and the growing chance of a recession.

06:06 13 Aug 2022 CLVS

CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--First paragraph, second sentence of release should read: Clovis' senior management will host a conference call and live audio webcast at 8:30am ET to discuss Clovis' results and business outlook in greater detail. (instead of Clovis' senior management will host a conference call and live audio webcast at 6:30am ET to discuss Clovis' results and business outlook in greater detail.). The updated release reads: CLOVIS ONCOLOGY TO ANNOUNCE SECOND QUARTER 2022 FINANC

04:00 13 Aug 2022 CLVS

Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2022 financial results and provide an update on its clinical development programs and regulatory and business outlook on Monday, August 8, 2022, before the open of the US financial markets. Clovis' senior management will host a conference call and live audio webcast at 6:30am ET to discuss Clovis' results and business outlook in greater detail. The conference call will be simultaneously webcas

03:43 13 Aug 2022 CLVS

Why Clovis Oncology Stock Trounced the Market Today

Investors were cheered by news of a freshly signed supply deal.

12:17 13 Aug 2022 CLVS

Clovis Oncology (CLVS) Stock Pops 7% on Supply Agreement

CLVS stock is rallying 7% after Clovis Oncology made a major deal with NorthStar Medical. Takeover speculation has swirled around Clovis.

09:53 13 Aug 2022 CLVS

Why Clovis Oncology Stock Went Into Retreat Mode This Week

After a massive surge in its share price recently, Clovis Oncology has started to reverse course.

Financial details

Company Rating
Neutral
Market Cap
238.84M
Income
-198.25M
Revenue
110.7M
Book val./share
-2.5
Cash/share
1.01
Dividend
-
Dividend %
-
Employees
413
Optionable
Yes
Shortable
Yes
Earnings
01 Nov 2022
P/E
-1.05
Forward P/E
-
PEG
0.17
P/S
2.89
P/B
-0.58
P/C
1.47
P/FCF
-1.74
Quick Ratio
0.93
Current Ratio
0.78
Debt / Equity
-1.44
LT Debt / Equity
-1.44
-
-
EPS (TTM)
-1.7
EPS next Y
-
EPS next Q
-0.44
EPS this Y
-50.18%
EPS next Y
-
EPS next 5Y
11.98%
EPS last 5Y
-21.58%
Revenue last 5Y
21.79%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-34.62%
SMA50
125%
SMA100
-1.29%
Inst Own
43.59%
Inst Trans
-10.47%
ROA
-52%
ROE
69%
ROC
-0.74%
Gross Margin
63%
Oper. Margin
-273%
Profit Margin
-275%
Payout
-
Shs Outstand
143.88M
Shs Float
141.82M
-
-
-
-
Target Price
-
52W Range
0.58-5.06
52W High
-
52W Low
-
RSI
44.16
Rel Volume
0.25
Avg Volume
13.06M
Volume
3.24M
Perf Week
-10.3%
Perf Month
-17.78%
Perf Quarter
-13.45%
Perf Half Y
-27.8%
-
-
-
-
Beta
0.488718
-
-
Volatility
0.12%, 0.42%
Prev Close
2.07%
Price
1.48
Change
-1.33%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
1.181.832.651.951.23
Net income per share
-7.36-7.07-7.43-4.38-2.18
Operating cash flow per share
-5.55-7.03-6.01-3-1.62
Free cash flow per share
-5.63-8.26-6.36-3.1-1.62
Cash per share
11.989.995.512.851.18
Book value per share
7.812.81-3.23-1.88-2.3
Tangible book value per share
6.010.6-5.57-3.41-3.32
Share holders equity per share
7.812.81-3.23-1.88-2.3
Interest debt per share
6.2211.3313.027.955.53
Market cap
2.87B1.28B464.39M666.03M233.95M
Enterprise value
2.69B1.64B987.7M1.07B728.89M
P/E ratio
-8.28-3.48-1.16-1.8-0.88
Price to sales ratio
51.6713.433.254.051.57
POCF ratio
-10.99-3.5-1.43-2.64-1.19
PFCF ratio
-10.82-2.98-1.36-2.55-1.19
P/B Ratio
7.88.74-2.66-4.2-0.84
PTB ratio
7.88.74-2.66-4.2-0.84
EV to sales
48.417.156.916.524.9
Enterprise value over EBITDA
-7.97-4.68-2.64-3.17-3.24
EV to operating cash flow
-10.3-4.47-3.05-4.24-3.72
EV to free cash flow
-10.14-3.8-2.88-4.11-3.71
Earnings yield
-0.12-0.29-0.86-0.55-1.13
Free cash flow yield
-0.09-0.34-0.74-0.39-0.84
Debt to equity
0.773.93-3.9-3.64-2.25
Debt to assets
0.50.831.261.261.59
Net debt to EBITDA
0.54-1.01-1.4-1.2-2.2
Current ratio
7.694.552.751.681.58
Interest coverage
-22.79-25.32-22.77-12.86-7.13
Income quality
0.750.990.810.680.74
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
2.51.841.2800
Research and developement to revenue
2.572.431.981.571.29
Intangibles to total assets
0.120.130.190.210.26
Capex to operating cash flow
0.020.180.060.030
Capex to revenue
-0.07-0.67-0.13-0.050
Capex to depreciation
-1.64-13.96-2.45-1.02-0.04
Stock based compensation to revenue
0.810.510.380.310.17
Graham number
35.9821.1523.2613.6210.63
ROIC
-0.36-0.45-0.7-0.72-0.65
Return on tangible assets
-0.53-0.49-0.74-0.77-0.76
Graham Net
4.59-3.3-9.43-5.76-4.75
Working capital
545.42M446.55M233.38M125.9M72.87M
Tangible asset value
282.86M31.47M-300.25M-287.57M-402.29M
Net current asset value
259.35M-144.79M-477.39M-453.47M-553.59M
Invested capital
0.773.94-3.93-4.08-2.29
Average receivables
19.41M22.88M32.63M30.6M32.14M
Average payables
20.92M27.6M29.46M26.69M27M
Average inventory
29.11M28.89M28.62M30.71M22.2M
Days sales outstanding
5458.0288.4667.8882.62
Days payables outstanding
471.04471.54339.23235.87256.72
Days of inventory on hand
855.45447.64279.06271.41128.68
Receivables turnover
6.766.294.135.384.42
Payables turnover
0.770.771.081.551.42
Inventory turnover
0.430.821.311.342.84
ROE
-0.94-2.512.32.330.95
Capex per share
-0.09-1.23-0.35-0.10

Quarterly Fundamentals Overview

Last date of statement is 2022-03-31 for Q1

Metric History 2021-03-312021-06-302021-09-302021-12-31 2022-03-31
Revenue per share
0.370.340.310.30
Net income per share
-0.64-0.61-0.56-0.530
Operating cash flow per share
-0.59-0.43-0.38-0.34-0.48
Free cash flow per share
-0.59-0.43-0.38-0.34-0.48
Cash per share
1.832.121.421.181.01
Book value per share
-2.12-1.91-1.86-2.3-2.5
Tangible book value per share
-3.34-3.07-2.89-3.32-2.51
Share holders equity per share
-2.12-1.91-1.86-2.3-2.5
Interest debt per share
6.446.285.215.333.61
Market cap
731.81M629.19M540.63M328.5M244.86M
Enterprise value
1.21B1.07B992.3M823.44M559.9M
P/E ratio
-2.76-2.37-2-1.280
Price to sales ratio
19.2317.0914.269.130
POCF ratio
-11.82-13.46-11.74-7.95-4.19
PFCF ratio
-11.8-13.45-11.71-7.93-4.19
P/B Ratio
-3.31-3.04-2.4-1.18-0.81
PTB ratio
-3.31-3.04-2.4-1.18-0.81
EV to sales
31.6729.126.1722.890
Enterprise value over EBITDA
-21.23-19.11-17.35-15.050
EV to operating cash flow
-19.47-22.92-21.54-19.92-9.57
EV to free cash flow
-19.44-22.9-21.5-19.88-9.57
Earnings yield
-0.09-0.11-0.12-0.20
Free cash flow yield
-0.08-0.07-0.09-0.13-0.24
Debt to equity
-2.69-2.92-2.75-2.25-1.44
Debt to assets
1.41.361.441.591.67
Net debt to EBITDA
-8.34-7.89-7.9-9.050
Current ratio
1.461.72.051.580
Interest coverage
-7.84-7.07-7.03-6.630
Income quality
0.930.70.680.640
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
1.391.31.311.160
Intangibles to total assets
0.230.220.250.260
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
-0.05-0.02-0.04-0.030
Stock based compensation to revenue
0.110.20.180.20
Graham number
5.515.134.825.240
ROIC
-0.15-0.14-0.15-0.150
Return on tangible assets
-0.16-0.15-0.18-0.180
Graham Net
-5.26-4.74-4.37-4.75-5.22
Working capital
79.28M122.47M117.97M72.87M0
Tangible asset value
-348.51M-333.11M-350.25M-402.29M-304.65M
Net current asset value
-517.36M-482.86M-502.79M-553.59M-632.59M
Invested capital
-3.01-3.25-2.77-2.29-1.44
Average receivables
30.06M31.75M32.47M33.67M0
Average payables
23.91M24.89M25.57M27.31M0
Average inventory
17.93M19.34M15.48M13.69M0
Days sales outstanding
62.5472.974.1984.260
Days payables outstanding
191.99209.93217.71252.590
Days of inventory on hand
207.57233.41157.88126.610
Receivables turnover
1.441.231.211.070
Payables turnover
0.470.430.410.360
Inventory turnover
0.430.390.570.710
ROE
0.30.320.30.230
Capex per share
00000

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap